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Abstract: “Metagenres” such as directives, regulations and institutional guidelines regulate and reinforce typicality in terms 
of the macro- and microstructure of other genres. The notion of metagenre helps to elaborate the legal, ideological and power 
operations of genre systems within institutional contexts and between institutions and companies or individuals (Schryer & 
Spoel, 2005). I will present the genre system which systematizes “medicinal product information genres” and the restrictions 
and conventions imposed by metagenres which implement healthcare rules and are issued by regulatory authorities.
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Metagéneros e información sobre medicamentos
Resumen: Ciertos «metagéneros», como las directivas, los reglamentos y las directrices institucionales, regulan la macroestructura 
y la microestructura de otros géneros reforzando su tipicidad. El concepto de metagénero nos ayuda a entender las relaciones 
legales, ideológicas y de poder que se establecen en el seno de los sistemas de géneros, tanto en contextos institucionales, 
como en las relaciones entre instituciones y personas físicas o jurídicas (Schryer y Spoel, 2005). En esta aportación presentaré 
el sistema de géneros que engloba los géneros relativos a la «información sobre medicamentos», así como las restricciones 
y convenciones impuestas por los metagéneros en los que se materializan las normativas sanitarias emitidas por las autoridades 
competentes.
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1. Introduction
Genre systems focus on interaction among genres, 
and thus many collaborative uses of communication in 
professional domains may be analysed through such a lens, 
which specifically addresses the contextual and temporal 
interconnections between individual genres.
I suggest that practising and prospective medical writers 
and translators, in the pharmaceutical sector, and even 
healthcare communication teachers, may find the description 
of the medicinal product information genre system and the 
metagenres that interact with the genre system especially 
useful, as it may facilitate and optimise the process whereby 
individuals learn the culture of the professional group they 
are working with, through experience, observation and 
instruction.
Medicinal products are highly regulated in the European 
Union (EU) and are subject to a complicated system of 
approvals that governs how, when, where, and in what 
form such products will be allowed to be sold within the 
EU. The process of providing product information on a 
medicinal product for its marketing, sale and use involves a 
sequence of interrelated communicative actions structured 
in a system of genres that I have called the medicinal 
product information genre system (Ezpeleta Piorno, 2012). 
I will present the application procedures, the genres of 
the genre system, the metagenres interacting with them and 
the participants involved.
2. Genre systems and metagenres
Studies in genre provide an especially useful framework 
to explore texts in their social contexts. They are particularly 
productive for understanding the connections between spe-
cific communication practices and the activity of professional 
groups (Borja, 2005).
The notion of genre system refers to the existence of 
interdependent genres which appear as certain typical 
sequences and which form relations with one another 
and have interacting purposes and forms (Bazerman, 
1994; Ezpeleta Piorno & Gamero Pérez, 2004; Spinuzzi, 
2003; Yoshioka, Herman, Yates, & Orlikowski, 2003). 
Moreover, understanding the rhetorical motives, structures 
and functions of specific genres requires recognition 
of their interconnections with other genres in a specific 
communicative context within and across the professional 
communities that use them or bring them into play.
In the pharmaceutical sector, for example, the summary 
of product characteristics is part of a genre system, together 
with the company core data sheet, the product profile, the 
package leaflet, and medicinal product advertisements, 
amongst others. In order to market and sell any medicine in 
the European Union, all these genres will be interacting in a 
complex communicative network.
According to Giltrow (2001: 190), a “metagenre is 
situated language about situated language”. In her research 
on mental health discourse, Berkenkotter (2001: 339) has 
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demonstrated that certain genres, such as professional 
manuals, can have metageneric functions for standardising 
and mediating the localised epistemological communicative 
practices of psychiatrists. She has explained that metagenres 
can be seen as “a mediational means or tool for stabilizing 
practices”. Thus metagenres such as directives, regulations 
or institutional guidelines regulate and reinforce typicality in 
terms of the macro- and microstructure of other genres, they 
can be constraining and enabling, “ruling out certain kinds of 
expression, endorsing others” (Giltrow, 2001: 191).
3. The medicinal product information genre system and 
application procedures
The primary purpose of the rules governing medicinal 
products is to safeguard public health. However, European 
authorities consider that this objective must be achieved 
by means which do not hinder the development of the 
pharmaceutical industry or trade in medicinal products within 
the Community. Thus the pharmaceutical legislation of the 
EU consistently pursues two objectives: the protection of 
public health and the free movement of medicinal products.
Before they can be placed on the EU market, all medicinal 
products for human use have to be authorised either at 
Community or member state level. The procedures for 
application for a marketing authorisation in the EU are the 
centralised procedure and the national procedure. 
Via the centralised procedure, European approvals of 
medicines are overseen by the European Medicines Agency 
(EMA). The application is scientifically evaluated by the 
Committee for Medicinal Products for Human Use (CHMP). 
This procedure results in a single marketing authorisation that 
is valid in all EU countries, as well as in Iceland, Liechtenstein 
and Norway, allowing the marketing authorisation holder to 
make the medicine available to healthcare professionals and 
patients. The centralised procedure is mandatory for human 
medicines for the treatment of acquired immune deficiency 
syndrome (HIV/AIDS), cancer, diabetes, neurodegenerative 
diseases, auto-immune and other immune dysfunctions, and 
viral diseases; biotechnological medicinal products, such 
as genetic engineering; advanced-therapy medicines, such 
as gene-therapy, somatic cell-therapy or tissue-engineered 
medicines; and officially designated “orphan medicines” 
(medicines used for rare human diseases). For medicines that 
do not fall within these categories, companies have the option 
of submitting an application to the EMA for a centralised 
marketing authorisation, as long as the medicine concerned is 
a significant therapeutic, scientific or technical innovation, or 
if its authorisation would be in the interest of public health.
The documents required for the grant of a centralised 
marketing authorisation (summary of product characteristics, 
labelling, and package leaflet) have to be translated into all 
EU official languages as well as Norwegian and Icelandic.
If an applicant wishes to obtain a licence in one member 
state, through the national procedure, an application must be 
made to the national Competent Authority, which then issues 
a national licence. With the exception of products granted a 
marketing authorisation under the centralised procedure, as set 
out above, all products are granted marketing authorisations 
on a country-by-country basis by the competent authorities in 
each member state.
There are also two other possible routes available to 
companies for the authorisation of these medicines in several 
countries simultaneously: the decentralised procedure and the 
mutual recognition procedure. These procedures are based on 
the idea that a licence approved in one member state should 
be mutually recognised in other member states, assuming that 
the evaluation criteria in the EU member states are sufficiently 
harmonised and are of the same standard. Via the decentralised 
procedure companies can apply for simultaneous authorisation 
in more than one EU country of a medicine that has not yet 
been authorised in any EU country and that does not fall 
within the mandatory scope of the centralised procedure. 
Through the mutual recognition procedure companies that 
have a medicine authorised in one EU member state can apply 
for this authorisation to be recognised in other EU countries 
(Directorate General for Health and Consumers (DGHC) of 
the European Commission, 2007).
3.1. The genres of the system and the metagenres
A genre system provides expectations about the content 
of the whole genre system as well as the sequence and 
content of its constituent genres. For the medicinal product 
information genre system, the constituent genres provide, 
with different degrees of specialisation and levels of detail, all 
the relevant information which is necessary and indispensable 
for the appropriate prescription and safe use of a particular 
medicinal product (Montalt Ressurrecció & González Davis, 
2007). 
The main genres involved are: the summary of product 
characteristics (SPC), the package leaflet (PL), the labelling, 
and medicinal product advertising texts. There are also other 
genres involved, such as the company core data sheet (CCDS), 
the company core safety information (CCSI), periodic safety 
update reports (PSURs), etc. This set of interdependent genres 
is implemented in a well-defined sequence, and their purpose 
and form typically interconnect.
Between the CCSD, the SPC, the PL, press releases and 
advertisements there is a wide spectrum of communicative 
situations of decreasing degrees of required expertise and 
formality. Thus, the series of interrelated communicative 
actions structured in the medicinal product information genre 
system is enacted within and across pharmaceutical and 
medical communities. 
The central document, the summary of product characteristics 
(SPC), is prepared by the manufacturer and may appear in the 
national compendia in the countries where it is sold. The SPC 
may also form the legal basis for advertising and promotional 
materials, as well as for reimbursement of the cost of the drug to 
the patient by insurance companies or the authorities, since use 
of the medicine for unapproved (unlabelled) indications may 
not be covered. It is written in accordance with the CCDS and 
the CCSI. These are prepared by the marketing authorisation 
holders and are not always made public (DGHC, 2009). The 
SPC provides all the information on the product that is essential 
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for the safe and efficacious use of the medicine, so that the 
benefits are maximised and the risks are minimised. It explains 
how to use and prescribe it, and includes a description of the 
characteristics of the product, its uses, dosing, contraindications, 
warning, pregnancy information, drug interactions and adverse 
events. The SPC does not give general advice on the treatment 
of particular medical conditions. On the other hand, specific 
aspects of the treatment related to use of the medicinal product 
or its effects must be mentioned. Similarly, general advice on 
administration procedures is not included but any advice specific 
to the medicinal product concerned has to be included.
The SPC, in turn, is the document on which the patient 
information leaflet and the labelling are based. The package 
leaflet (PL), also known as patient information leaflet (PIL) 
or package insert, consists of a summarised and simplified 
patient-friendly version of the SPC. The information provided 
and the way it is written and structured are intended to ensure 
that it is accessible to and can be understood by lay people so 
they can safely use the medicine concerned.
The SPC, the labelling and the PL must be included 
in the application for marketing authorisation. Once the 
authorisation has been obtained, pharmaceutical company 
representatives are legally obliged to provide the SPC to 
prescribers and dispensers. They must ensure that medicines 
will reach patients and users accompanied by the PL and with 
the approved labelling.
Advertising and other promotional material on medical 
products contributes to the information available but could 
affect public health. Thus, by regulation, an advertisement must 
comply with the particulars listed in the SPC. Also, medicinal 
products which do not have a marketing authorisation may not 
be advertised. A distinction is made between the advertising 
of medical products to the general public and to persons 
qualified to prescribe. The European regulations prohibit 
the advertising of prescription-only medicines (POM) to the 
general public. They also prohibit advertising to the general 
public of medicinal products for the treatment, prevention 
or diagnosis of certain diseases or conditions. Advertising to 
the general public of medicinal products legally classified as 
over-the-counter (OTC) products is allowed (Directive, 2001: 
70-95). 
In addition, there are a series of documents prepared by 
the marketing authorisation holder (MAH) which are not 
always made available to the public and which are used as 
reference for periodic safe reporting and in the preparation 
of the SPC. These include not only product information 
but also safety information, pharmacovigilance data, and 
other issues concerning the product. The company core 
data sheet (CCDS) or core data sheet (CDS) is a summary 
of the key characteristics of the product. In addition to 
safety information and pharmacovigilance data, it contains 
information on indications, dosing, pharmacology and other 
information concerning the product that is not necessarily 
applicable in all countries where the product is sold. MAHs 
often create a new document which is referred to as company 
core safety information (CCSI). This document contains 
the pharmacovigilance section of the CCDS in its entirety 
or a summary of it. It is intended as the minimum safety 
information for the product in all the countries of the world 
where that product is marketed. A CCDS may be created 
for a new product, to be available at the time of the initial 
submission of a national procedure application in its first 
market, or at any later point in a product’s life cycle. It is 
updated as necessary and accompanies the periodic safety 
update reports. Periodic safety update reports (PSURs) 
present the worldwide safety experience of a medicinal 
product at defined times post-authorisation, in order to: 
report all relevant new safety information from appropriate 
sources; relate these data to patient exposure; summarise the 
market authorisation status in different countries and any 
significant variations related to safety; periodically create the 
opportunity for an overall safety reevaluation; and indicate 
whether changes should be made to product information 
in order to optimise the use of the product (DGHC, 1986-
2012a, 1986-2012b).
The dynamics of institutional interrelations among the 
mentioned genres are set out in a series of metagenres such 
as directives, regulations and institutional guidelines, so as 
to guarantee the highest possible level of public health and to 
secure the availability of medicinal products to citizens across 
the European Union. Regulations are directly effective as 
supranational law and are addressed to the citizens of the EU 
member states. Directives are addressed to the member states 
and have to be implemented in national law by the legislation 
of the member states. Guidelines are not legally binding, but 
where an applicant chooses not to comply with a guideline, 
that decision must be explained and justified. Guidelines 
are addressed to professional writers and scientific staff of 
authorities and companies. For the purposes of this article, 
these metagenres will be considered as tools for stabilising 
practices which rule the flow of information and the way it 
has to be provided. 
The rules and regulations governing medicinal products 
for human use in the European Union are collected in 
Volume 1 (Pharmaceutical Legislation for Medicinal 
Products for Human Use) of The Rules Governing Medicinal 
Products in the European Union (DGHC, 1986-2012a). The 
legislation is supported by a series of guidelines compiled in 
Volume 2 (Pharmaceutical Legislation Notice to applicants 
and regulatory guidelines medicinal products for human 
use) of the same publication (DGHC, 1986-2012b). These 
institutional guidelines are related to procedural and 
regulatory requirements such as renewal procedures, dossier 
requirements, variation notifications, summary of product 
characteristics and package leaflet requirements, and 
classification for the supply and readability of the labelling 
and package leaflet requirements.
Advertising and promotional material of medical products 
is also subject to strict and specific control measures and 
effective monitoring by the European and local authorities. 
Directive 2001/83/EC of the European Parliament and of 
the Council of 6 November 2001 on the Community code 
relating to medicinal products for human use establishes a 
Community code which brings together, in a single instrument, 
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all the provisions in force governing the placing on the 
market, production, labelling, classification, distribution and 
advertising of medicinal products for human use (Directive, 
2001: 70-95). Specifically, the advertising of medicines is 
controlled by medicines regulatory authorities in member 
states and other national regulatory bodies, together with 
self-regulation by the pharmaceutical industry. However, The 
Directorate General for Health and Consumers (DGHC) of 
the European Commission exercises supervision to ensure 
that the distribution of information to prescribers, dispensers 
and the general public, and its content and placing, are in 
accordance with European laws on product safety, consumer 
rights and public health in all EU countries.
All EU directives, regulations, guidelines, points to consider, 
recommendations and procedures for the regulation of human 
medicines can also be consulted at the European Medicines 
Agency website (European Medicines Agency, 1995-2012).
3.2. The participants
The range of participants involved in the process of 
providing information for the marketing, sale and use of 
products is very wide. They are: researchers and scientific 
staff and medical writers and linguistic mediators working 
for pharmaceutical companies or marketing authorisation 
holders, who generate the genre system and compose the 
various documents involved in the process; the authorities, 
which regulate and supervise the process; the receivers, who 
are the competent intermediaries; healthcare professionals, 
prescribers and dispensers; and, finally, patients and the 
general public who use the product. 
According to the European Medical Writers Association, 
the tasks performed by medical writers and linguistic 
mediators mainly concern the communication of clinical and 
scientific data and information to a range of audiences in a wide 
variety of formats. They have to combine good knowledge 
of science and research skills with an understanding of how 
to present information. They also have to be able to pitch 
it at the right level for the intended audience. Usually, their 
background is a medical or life science qualification (e.g. 
biology, biochemistry, physiology or chemistry). However, 
there are many medical writers and translators who enter the 
profession with backgrounds in language rather than science. 
The competence required is a high-level understanding of 
basic human anatomy and physiology, a good knowledge of 
diseases and their treatment, and, of course, very good writing 
and word-processing skills. Medical writers and translators 
also need to have good interpersonal skills, for, as we have 
seen through this paper, they collaborate in interdisciplinary 
teams (European Medical Writers Association, n.d.). They 
usually work for pharmaceutical companies, contract research 
organisations (CROs) or communications agencies. 
In a pharmaceutical company, medical writers prepare 
documents for submission to the regulatory authorities and 
manuscripts for publication. However, depending on the 
company, they may also be involved in other writing projects, 
such as training manuals, promotional material for marketing 
purposes, and websites.
Contract research organizations (CROs) are services 
companies that support pharmaceutical, medical device or 
biotechnology companies. They provide such services as 
biopharmaceutical development, preclinical research, clinical 
research and clinical trials management. Usually, they also offer 
services in medical product information and marketing. They 
help pharmaceutical companies to get their products registered 
with international regulatory authorities, and offer their clients 
the expertise necessary to take a new medicinal product 
from conception to European Medicines Agency marketing 
approval, without the marketing authorisation holder having to 
maintain a staff for these purposes. In general, medical writers 
in CROs are involved with preparing a range of documents for 
these regulatory submissions, including summaries of product 
characteristics and product information leaflets.
Medical writers in communications agencies generally 
prepare manuscripts for publication, items for conferences 
(e.g. posters, abstracts and slide presentations), promotional 
items for pharmaceutical marketing, training material, and 
multimedia (e.g. websites).
The Marketing Authorisation Holder (MAH) is the 
company or firm in whose name the marketing authorisation 
has been granted. This party is responsible for all aspects of the 
product, including quality and compliance with the conditions 
of marketing authorisation. The authorisation holder must be 
subject to legislation in the country that issued the marketing 
authorisation, which normally means being physically located 
in the country, or the European Union. Companies or firms 
have to be established in accordance with the law of a member 
state and have their registered office, central administration or 
principal place of business within the Community. They have 
to be constituted under civil or commercial law, including 
co-operative societies, non-profit-making organisations and 
other legal persons governed by public or private law.
In order to help ensure the highest possible level of public 
health protection within the European Union, the EU established 
the European Medicines Agency (EMA) in 1994. The EMA 
is a decentralised agency of the EU, located in London, with 
the main task of coordinating the scientific evaluation of the 
quality, safety and efficacy of medicinal products that undergo 
an authorisation procedure and providing scientific advice of 
the highest possible quality. The Agency is also responsible 
for the linguistic review process of product information in the 
centralised procedure. The document Operational procedure 
on the linguistic review process of product information in the 
centralised procedure – human presents the review process 
within the Commission’s Decision-Making Process (DMP) 
timeframes and provides details on its practical implementation 
(European Medicines Agency, 2011).
In addition, once a medicinal product has been authorised 
in the Community and placed on the market, its safety is 
monitored throughout its entire lifespan to ensure that in the 
event of adverse reactions that present an unacceptable level 
of risk under normal conditions of use, it is rapidly withdrawn 
from the market. This is done through the EU system of 
pharmacovigilance (which is beyond the scope of this article). 
Six scientific committees, composed of members of all 
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European Union (EU) and European Economic Area (EEA)-
European Free Trade Association (EFTA) states, conduct the 
main scientific work of the Agency: 
Committee for Medicinal Products for Human Use ••
(CHMP); 
Committee for Medicinal Products for Veterinary Use ••
(CVMP); 
Committee for Orphan Medicinal Products (COMP); ••
Committee on Herbal Medicinal Products (HMPC); ••
Paediatric Committee (PDCO);••
Committee for Advanced Therapies (CAT). ••
The Working Group on the Quality Review of Documents 
(QRD) provides assistance to the Agency’s scientific 
committees and to companies on linguistic aspects of the 
product information (summary of product characteristics, 
labelling and package leaflet) for medicines (Quality Review 
of Documents Group, 2012). It was established in June 1996 
and is composed of representatives from member states’ 
national authorities, the European Commission and the 
Agency. The QRD’s tasks include:
ensuring linguistic clarity, consistency and accuracy ••
of the product information; 
verifying the terminology used in translations and ••
their consistency with the original versions; 
promoting legibility of product information; ••
reviewing and updating templates for opinions of the ••
scientific committees and for product information, 
to ensure compliance with European Union rules on 
medicinal products and taking practical experience 
into account; and
contributing to the development of a common ••
understanding on the implementation of legislation 
and guidelines in relation to product information and 
labelling. 
The Directorate General for Health and Consumers 
(DGHC) of the European Comission, among other, has 
monitoring responsibilities. It exercises supervision to ensure 
that the that the distribution of information to prescribers, 
dispensers and the general public, and its content and placing, 
are in accordance with European laws on product safety, 
consumer rights and public health.
4. Conclusion
In this work, I propose that the notion of genre systems can 
help us to understand how communicative actions are carried 
out by professional communities. In particular, we have seen 
the complex communicative processes of medicinal product 
information in the pharmaceutical sector, and the activities 
and roles played by the different agents involved.
I have presented the medicinal product information genre 
system, the interconnections among the main genres involved, 
the institutional metagenres interacting with them, and their 
settings and users. I have explained how metagenres interact 
with the genre system, how they regulate the interaction and 
sequence of the salient constituent genres of the system.
It is suggested that knowledge of these dimensions 
and of the institutional operations of metagenres can play 
an important role in the socialisation of medical writers 
and linguistic mediators as communicative agents of the 
pharmaceutical sector.
This work may also contribute to the development of 
conceptual and cognitive resources for communication 
researchers interested in medical communication processes, 
and to the improvement of tools for the teaching and 
acquisition of medical writing competence, in its formal, 
social and cognitive aspects.
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